Loading...
XHKG
0690
Market cap56mUSD
May 15, Last price  
0.08HKD
1D
0.00%
1Q
32.14%
Jan 2017
-51.63%
Name

Uni-Bio Science Group Ltd

Chart & Performance

D1W1MN
XHKG:0690 chart
P/E
5.54
P/S
0.83
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
-0.45%
Rev. gr., 5y
21.43%
Revenues
553m
+14.08%
94,949,000340,894,000869,946,000526,270,000148,286,00076,764,00057,026,00083,333,000102,624,000122,390,636123,364,000146,489,000156,477,000135,258,000209,449,000208,776,000353,405,000440,316,000484,718,000552,980,000
Net income
83m
+16.79%
-42,160,00060,316,000198,380,000-508,323,000-454,653,000-185,156,000-102,864,000-69,308,000-366,130,000-56,578,653-59,799,000-55,727,000-279,309,000-138,567,0002,459,000-71,319,000-19,591,00038,512,00070,876,00082,774,000
CFO
0k
-100.00%
-705,00086,804,00091,214,00073,542,00081,148,000-29,983,000-37,508,000-20,243,00049,991,000-79,702,647-12,595,000-23,691,000-68,605,000-89,000,000-30,749,000-15,474,00012,042,00048,660,00098,849,0000
Dividend
Aug 22, 20070.00157 HKD/sh
Earnings
May 16, 2025

Profile

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.
URL
https://www.uni-bioscience.com/
IPO date
Nov 12, 2001
Employees
340
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
552,980
14.08%
484,718
10.08%
440,316
24.59%
Cost of revenue
456,433
416,950
399,522
Unusual Expense (Income)
NOPBT
96,547
67,768
40,794
NOPBT Margin
17.46%
13.98%
9.26%
Operating Taxes
8,396
5,024
4,775
Tax Rate
8.70%
7.41%
11.71%
NOPAT
88,151
62,744
36,019
Net income
82,774
16.79%
70,876
84.04%
38,512
-296.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
(5,167)
BB yield
1.13%
Debt
Debt current
49,485
18,697
15,202
Long-term debt
81,577
48,822
18,948
Deferred revenue
Other long-term liabilities
2,709
Net debt
(62,839)
(70,955)
(127,022)
Cash flow
Cash from operating activities
98,849
48,660
CAPEX
(59,738)
(28,430)
Cash from investing activities
(76,144)
(27,029)
Cash from financing activities
24,513
2,575
FCF
23,447
15,690
28,482
Balance
Cash
183,902
129,236
98,216
Long term investments
9,999
9,238
62,956
Excess cash
166,252
114,238
139,156
Stockholders' equity
325,645
(1,781,213)
(557,010)
Invested Capital
277,289
2,094,686
771,316
ROIC
7.43%
4.38%
4.72%
ROCE
21.77%
21.59%
19.04%
EV
Common stock shares outstanding
6,140,106
6,364,768
6,360,659
Price
0.06
-16.67%
0.07
0.00%
0.07
-14.29%
Market cap
368,406
-19.61%
458,263
0.06%
457,967
-14.43%
EV
305,567
387,308
330,945
EBITDA
96,547
84,650
58,340
EV/EBITDA
3.16
4.58
5.67
Interest
783
376
Interest/NOPBT
1.16%
0.92%